Key Decisions in HIV Care: Treatment Considerations for Transgender PWH
Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for ART management for transgender PWH, including providing care within a gender-affirmative care model, considering drug–drug interactions between hormone therapy and ART, and addressing barriers to engagement and retention in care.
Decera Clinical Education Infectious Disease Podcast · Michelle D. Collins-Ogle MD FAAP FPIDS AAHIVS, Michelle D. Collins-Ogle
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH).
Listen as she gives perspectives on:
- Department of Health and Human Services (DHHS) guideline recommendations for transgender PWH
- Providing HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitators
- Gender-affirmative hormone therapy options
- Drug–drug interaction potential between gender-affirmative hormone therapy and antiretroviral therapy
- Recommended laboratory monitoring while receiving gender-affirming hormone therapy
- The cascade of care for transgender PWH and barriers to engagement and retention in care
Presenter:
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York
Follow along with the slides at:
https://bit.ly/3wOdKVo
Link to full program:
https://bit.ly/3fOl0XX
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.